Safety and Immune Response of Increasing Doses of OVX836 After Intramuscular or Intranasal Administrations in Healthy Subjects

Influenza Clinical Trial

Official title:

A First-in-human Phase I, Single Center, Randomized, Observer-blind, Placebo-controlled Study to Evaluate the Safety and Immune Response of Increasing Doses of OVX836 Vaccine After Intramuscular (IM) or Intranasal (IN) Administrations in Healthy Subjects Aged 18-49 Years.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03594890
• Other study ID #: OVX836-001
• Status: Completed
• Phase: Phase 1
• Start date: June 12, 2018
• Est. completion date: August 7, 2019

Study information

• Verified date: September 2022
• Source: Osivax
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The present study is a first-in-man clinical trial evaluating OVX836, a recombinant broad spectrum vaccine for Influenza. This clinical trial will evaluate the safety and the immune response of increasing doses of OVX836 after intramuscular or intranasal administrations in healthy volunteers.

Description:

This study is a single center, randomized, sequential dose escalation, placebo-controlled, observer-blind study conducted in healthy subjects aged 18-49 years. The OVX836 recombinant vaccine is based on the well conserved nucleoprotein of the Influenza virus. Three different dose levels of OVX836 (30µg, 90µg, 180µg) will be assessed sequentially and administered either by the intramuscular route (Study Part A) or by the intranasal route (Study Part B). There will be 6 cohorts in total with one cohort testing one dose level and one route of administration. Each study cohort will be composed of 12 subjects, with 9 subjects receiving the OVX836 vaccine and 3 subjects receiving the placebo. Each subject will receive one administration of OVX836 or placebo on Day 1 and one administration on Day 29. The study duration for each subject is approximately 5 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 72
• Est. completion date: August 7, 2019
• Est. primary completion date: August 7, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 49 Years

Eligibility

Inclusion Criteria:

1. Have given written informed consent approved by the relevant Ethical Committee governing the site.

2. Overtly healthy male or female subjects, as determined by medical history and medical examination.

3. Between the ages of 18 and 49 years, inclusive, on screening.

4. Between the Body Mass Index of 18 and 24 kg/m2, inclusive, on screening.

5. Clinical laboratory test results within normal reference range, or results with acceptable deviations that are judged to be Non Clinically Significant by the Investigator.

6. Blood Pressure and Heart Rate within normal reference range, or results with acceptable deviations that are judged to be Non Clinically Significant by the Investigator.

7. Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.

Exclusion Criteria:

1. Previous Influenza vaccination within the 6 months before screening.

2. History of significant medical illness such as auto immune diseases, immune deficiency, uncontrolled diabetes or hypertension, heart or renal or hepatic diseases, as judged by the investigator.

3. For female subjects: pregnant or breast-feeding or of childbearing potential without appropriate contraceptive methods or with positive pregnancy test at screening.

4. Having received another vaccination within 3 months prior to screening.

5. Plan to receive other vaccine during the study period.

6. Administration of any investigational or non-registered drug or vaccine within 3 months prior to the first administration of study vaccine.

7. History of receiving blood or blood component or IgG within 3 months prior to screening.

8. Presence of acute febrile illness (temperature > 38°C, temporary exclusion criteria).

9. For intranasal route: common cold and rhinitis (temporary exclusion criteria).

10. Individuals with any progressive or severe neurological disorder, seizure disorder or Guillain-Barré syndrome.

11. Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the Investigator, may interfere with the subject's ability to participate in the study.

12. History of alcoholism and/or drug abuse or tabagism (above 10 cigarettes a day).

13. Treatment that can affect immune response such as systemic or high dose inhaled corticosteroids (>800µg/day beclometasone or equivalent), radiation treatment, cytotoxic drugs or chronic non-steroidal anti-inflammatory drugs (more than 4 weeks), interferon, immunomodulators, allergy shots, as judged by the Investigator.

14. Positive test for HIV, HBV or HCV at screening.

15. History of severe allergic reactions and/or anaphylaxis or serious adverse reactions to vaccines and antibiotics.

16. Any contraindication to intranasal or intramuscular administration, as judged by the Investigator.

17. Individuals with history of any illness that, in the opinion of the Investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.

18. Sponsor employees or Investigator site personnel directly affiliated with this study, and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted.

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Intervention

Biological:
• OVX836 (Intramuscular)
2 consecutive administrations of OVX836 vaccine at Day 1 and Day 29.
• Placebo (Intramuscular)
2 consecutive administrations of placebo at Day 1 and Day 29.
• OVX836 (Intranasal)
2 consecutive administrations of OVX836 vaccine at Day 1 and Day 29.
• Placebo (Intranasal)
2 consecutive administrations of placebo at Day 1 and Day 29.

Locations

Country	Name	City	State
Belgium	Centre for the Evaluation of Vaccination, University of Antwerp	Antwerpen

Sponsors (2)

Lead Sponsor	Collaborator
Osivax	Aepodia

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Out-of-Range Safety Lab data	Frequency (number and percentage) of subjects with deviations from normal values of hematological and biochemical blood tests	28 days after last vaccine administration.
Primary	Safety: Solicited local and systemic reactions	Frequency (number and percentage) of subjects with reported solicited local and systemic reactions	7 days after last vaccine administration.
Primary	Safety: Unsolicited Adverse Events	Frequency (number and percentage) of subjects with reported unsolicited Adverse Event (AE)	28 days after last vaccine administration.
Primary	Safety: Serious Adverse Events	Frequency (number and percentage) of subjects with reported Serious Adverse Event (SAE)	at end of study visit (i.e. Week 22)
Secondary	Immune response: frequency of subjects with anti-NP IgG antibody titres	Frequency (number and percentage) of subjects with an increase of anti-NP Immunoglobulin G (IgG) (ELISA, serum) for each dose level of OVX836 administered by the intramuscular or intranasal route.	28 days post each vaccine administration and 5 months after the 1st vaccine administration (i.e. Day 29, Day 57, Day 150) versus Day 1 pre-dose.
Secondary	Immune response: anti-NP IgG antibody titres (geometric mean)	Geometric Mean in anti-NP Immunoglobulin G (IgG) (ELISA, serum) for each dose level of OVX836 administered by the intramuscular or intranasal route.	28 days post each vaccine administration and 5 months after the 1st vaccine administration (i.e. Day 29, Day 57, Day 150) versus Day 1 pre-dose.
Secondary	Immune response: frequency of subjects with anti-NP IgA antibody titres	Frequency (number and percentage) of subjects with an increase of Anti-NP Immunoglobulin A (IgA) (ELISA, nasal swab) for each dose level of OVX836 administered by the intranasal route.	28 days post each vaccine administration and 5 months post 1st vaccine administration (e.g. Day 29, Day 57, Day 150) versus Day 1 pre-dose.
Secondary	Immune response: anti-NP IgA antibody titres (geometric mean)	Geometric Mean in anti-NP Immunoglobulin A (IgA) (ELISA, serum) for each dose level of OVX836 administered by the intranasal route.	28 days post each vaccine administration and 5 months post 1st vaccine administration (e.g. Day 29, Day 57, Day 150) versus Day 1 pre-dose.
Secondary	Immune response: frequency of subjects with NP T cell resoonse	Frequency (number and percentage) of subjects with NP T cell response (ELISPOT, Peripheral Blood Mononuclear Cells (PBMC)) for each dose level of OVX836 by the intramuscular or intranasal route.	Day 1 pre-dose, 7 days and 28 days post each vaccine administration, and 5 months post 1st vaccine administration (e.g. Day 1, Day 8, Day 29, Day 36, Day 57, Day 150).
Secondary	Immune response: mean NP T cell response	NP T cell response (mean ELISPOT counts) for each dose level of OVX836 administered by the intramuscular or intranasal route.	Day 1 pre-dose, 7 days and 28 days post each vaccine administration, and 5 months post 1st vaccine administration (e.g. Day 1, Day 8, Day 29, Day 36, Day 57, Day 150).

External Links

•   Clinical Unit
•   Phase 1 Randomized, Placebo-Controlled, Dose-Escalating Study to Evaluate OVX836, a Nucleoprotein-Based Influenza Vaccine: Intramuscular Results
•   Sponsor